Enspryng

Enspryng is a medicine used to treat patients aged 12 or above with neuromyelitis optica spectrum disorders (NMOSD), inflammatory disorders that affect mainly the optic nerve (which connects the eye to the brain), and the spinal cord. This leads to impaired vision, loss of sensation, loss of bladder control, weakness and paralysis of the arms and legs. The medicine is used on its own or in combination with immunosuppressive therapy (treatment that reduces the activity of the immune system) in patients with antibodies against a protein called aquaporin-4 (AQP4). NMOSD is rare, and Enspryng was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 27 June 2016. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu3161680](/en/medicines/human/orphan-designations/eu-3-16-1680). Enspryng contains the active substance satralizumab.